Application of two versions of the WHO/international society of hypertension absolute cardiovascular risk assessment tools in a rural Bangladeshi population

Kaniz Fatema,1,2 Nicholas Arnold Zwar,2 Abul Hasnat Milton,3 Bayzidur Rahman,2 Liaquat Ali4

ABSTRACT

Objectives: To estimate the absolute cardiovascular disease (CVD) risk burden in a remote rural Bangladeshi population using the ‘With’ and ‘Without’ Cholesterol versions of the WHO/International Society of Hypertension (WHO/ISH) CVD risk assessment chart (particularly suitable for low and middle-income countries due to less reliance on laboratory testing) and to evaluate the agreement between the two approaches.

Design: Cross-sectional study using data from a large prospective cohort of the North Bengal Non-Communicable Disease Programme (NB-NCDP) of Bangladesh.

Setting: General rural population from Thakurgaon district of Bangladesh.

Participants: 563 individuals who were categorised as having ‘no CVDs’ on screening by a questionnaire-based survey using the ‘WHO CVD-Risk Management Package’ developed in 2002.

Main outcome measures: Absolute CVD risk burden assessed using two versions of the WHO/ISH risk assessment charts for the South-East Asian Region-D.

Results: 10-year risk (moderate, high and very high) positivity was present among 21.5% and 20.2% of participants, respectively, using with and without cholesterol versions of the tool. The overall concordance rate for the two versions was 89.5% and they did not differ significantly in estimating the proportion of overall participants having higher levels of CVD. The projected drug requirement, however, showed a significant overestimation in the proportion of participants at both the threshold levels (p<0.002) on using ‘without’ as compared to ‘with’ cholesterol versions.

Conclusions: About one-fifth of the adult population in Bangladesh, even in a remote rural area, seem to be at risk of developing CVDs (25% of them at high risk and 25% at very high risk) within 10 years with males and females being almost equally vulnerable.

INTRODUCTION

Cardiovascular diseases (CVDs) are now the major cause of death all over the world. It is estimated by the WHO that 17.5 million (31% of all death) people died from CVDs in 2012.1 Of all deaths, about 80% occurred in low-income and middle-income countries (LMICs).2 Accurate estimation of CVD risk is vital for both prevention and management of CVDs as well as for designing long-term policies and programmes to combat the challenges posed by them. It is now known that many of the risk factors such as smoking, hypertension, dyslipidaemia, diabetes, physical inactivity and obesity are potentially modifiable by health counselling.3 Available evidence suggests that absolute CVD risk assessment on the basis of the combined
effect of multiple risk factors yields a greater degree of accuracy than estimates based on individual risk factors. Moreover, existing evidence also indicates that the cost-effectiveness of management and treatment decisions, including the use of medicine, should be based on absolute CVD risk assessment.

Most of the existing CVD risk-profiling packages rely on equations based on Framingham and other similar studies (eg, PROCAM (Munster), Seven Countries Study, SCORE and Progetto CUORE studies). There is limited evidence of the applicability of these protocols in the context of developing countries, whose populations were not included in any of the aforementioned study samples. In 2000, after consultation with experts in all the WHO regions, the WHO released a risk-profiling tool tailored to developing countries that aimed to facilitate systematic case management at all healthcare levels. In 2007, this tool provided the framework for sets of regional risk prediction charts developed by the WHO and the International Society of Hypertension (WHO/ISH). These were based on risk factors that could be assessed by physician and non-physician health workers in a primary care setting in each of the 14 WHO sub-regions. In recognition of resource limitations of LMICs, these tools placed a low emphasis on laboratory investigations and aimed to guide the allocation of limited healthcare resources in the most cost-effective way among high-risk groups. Although the CVD risk scores were originally intended for a quick, consistent measure of absolute risk in individuals, through cross-sectional surveys of population samples, they could also provide a tool for estimating and monitoring population trends of CVD risks.

Bangladesh is an LMIC where the emerging challenge in the health sector is non-communicable diseases (NCDs) and, among all NCDs, the foremost cause of death and disability is CVDs. Approximately 13.4% of disability adjusted life years (DALYs) lost in Bangladesh are due to CVDs. These problems are exacerbated, especially in primary healthcare sectors, by socioeconomic obstacles, non-uniform accessibility to treatment, insufficient staffing of healthcare facilities and limited capacity for ancillary investigations.

Few LMICs currently have clinical guidelines either for screening or treatment of risk factors based on ‘absolute’ CVD risk scores, or any sort of estimate on the population distribution of CVD risks over time. In Bangladesh, studies aimed at risk estimation for CVDs are still limited in number and even those which have been conducted have mostly used an individual rather than multiple risk factor approach. Cravedi et al have conducted the only such study among urban and rural populations. However the rural population in this study was recruited from regions close to urbanised areas, so it may not represent the risk factor pattern in more remote rural populations. The present study was undertaken to assess the distribution of absolute CVD risk in a remote rural adult population, with and without cholesterol, using the WHO/ISH risk prediction charts and to compare the concordance between the two approaches with the tool including cholesterol treated as the gold standard. We also compared the projected drug requirements for CVD prevention based on each version of the assessment tool at risk thresholds of ≥20% and ≥30 for single risk factors in order to assess applicability of the tool in an LMIC setting.

**METHODS**

The selection of participants for the study has been described previously. Briefly, a prospective cohort of (190 471) residents in a rural area of Bangladesh was established in 2008 as part of the ‘BADAS-ORBIS Eye Care Project’. The main objective was designed to generate epidemiological data on the burden of diabetic retinopathy and associated risk factors. In 2011–2012, participants in the eye project cohort who had been aged between 31 and 74 in 2008 were invited to participate in the North Bengal Non-Communicable Disease Programme (NB-NCDP) of Bangladesh University of Health Sciences (BUHS). Of 66 701 eligible residents, 63 708 consented (participation rate 95.5%) and were screened for CVDs using the ‘WHO CVD-RISK Management Package for low and medium resource settings’. This questionnaire identified individuals at high risk of a CVD event on the basis of current symptoms or a history of pre-existing CVD. The screening process identified 1170 individuals as high risk, who were then immediately referred to the next level care, following the WHO package guidelines. Among the 62 538 remaining cohort members, 1000 participants were randomly selected with the expectation that in the future, after a 50% loss to follow-up, we would have sufficient participants to observe an association, as per a case cohort design. Of the 1000 people invited, 563 (56.3%) were willing to participate. The participants of this sub-cohort were checked for age, sex and education status with the main cohort and did not observe any significant difference between participants and non-participants.

Using a structured, pretested interviewer-administered questionnaire, information was collected on the following: sociodemographic and economic characteristics, a 5-day dietary intake history (including fruit and vegetable intake), current tobacco use (including type of smoking or non-smoked tobacco use), smoking history, passive smoking, alcohol intake (including local form of alcoholic beverages), physical activity (assessed by exact daily duration (minutes) of work-related, commute-related and leisure time-related physical activity) and history of medicine intake for any chronic disease. A health examination collected anthropometric

---

1Most of the existing research conducted in Bangladeshi rural settings has been in rural areas adjacent to urban spaces, whereas a remote rural area is one geographically and behaviourally distinct from urban influences.
measurements (ie, height, weight, waist and hip circumferences), blood pressure measurements ((BP), measured 3 times in sitting position), fasting and 2 hBG (2 h blood glucose after having 75 g oral glucose for the oral glucose tolerance test) and blood sample collection for biochemical measurements (ie, lipid profile). Whole capillary blood was taken and centrifuged serum was separated and refrigerated for analysis. Plasma glucose was measured by the glucose oxidase method using DimaisionRxL Max (Siemens AG, Erlangen, Germany) and plasma–TC was analysed by the enzymatic colorimetric method. Verbal consent in the presence of a witness was obtained for all participants.

Calculating absolute CVD risk using the WHO/ISH risk prediction charts
To classify absolute CVD risk, individuals were evaluated using the WHO/ISH risk assessment charts for the South-East Asian Region: D. The WHO and ISH have devised two sets of risk prediction charts—with and without blood cholesterol.11 18 Both sets require data on sex (male/female), age in years (31–49, 50–59, 60–69 and ≥70 years), systolic blood pressure (<140 mm Hg; 140–160 mm Hg; 160–180 mm Hg and ≥180 mm Hg), the mean of the last two of the three measurements taken in rested participants in sitting position, smoking status (no, yes, ex-smoker<12 months), presence or absence of diabetes status (yes/no, defined by fasting blood glucose ≥7 mmol/L) and record of oral hypoglycaemic drug use if blood sugar is measured below these threshold levels, in order to estimate risk of a cardiovascular event in the next 10 years. The chart developed for settings where blood cholesterol can be measured also uses blood cholesterol (total cholesterol in five categories: <5 mmol/L, 5–<6 mmol/L, 6–<7 mmol/L, 7–<8 mmol/L and ≥8 mmol/L). The charts provide evidence-based recommendations on the initiation of specific preventive actions (behavioural or pharmacological) and their intensity. In this study, we categorised the population according to the risk of developing a fatal or non-fatal severe CVD event (acute myocardial infarction and/or stroke) in the next 10 years into four levels: low, <10%; moderate, 10–19.9%; high, 20–29.9%; and very high risk, ≥30%.18 19 The WHO criteria and recommendations as well as expert consensus recommend drug therapy to prevent CVD in people with a CVD risk threshold ≥30%, or ≥20% if financially feasible.10 19–21

Statistical methods
Analysis was conducted using Stata V.12 (StataCorp LP, College Station, Texas, USA). Percentages with 95% CIs were calculated for categorical variables. Means, SDs and 95% CIs were calculated for continuous variables. Excel file 2005 (Microsoft) was used for CVD risk calculation, data entry and processing. For CVD risk prediction analysis, we used the method described in the WHO guidelines.10 We used the χ² test for statistical significance with a threshold of p<0.05. For data analysis, we used the method described in the WHO guidelines.22 Concordance between the two prediction charts was calculated for the different risk levels assuming the chart with cholesterol as the reference (ie, if CVD risk was classified higher without cholesterol, we described it as an overestimate; if lower, as an underestimate). Cohen’s k was used to observe the inter-rater agreement between with and without cholesterol for a 10-year CVD risk score.

RESULTS
Overview of the risk burden among study participants
After analysis, the overall demographic and social characteristics of all the study participants showed that male representation was higher (66.1%), about three-quarters of the participants (75%) had low or poor educational knowledge (ie, illiterate/only signature/gonoshikha and primary education) and almost 99% were from the low and lower middle-income group and 67.1% of them were from the physically active group (ie, homemaker/farmer) (data not shown on a table).

Distribution of individual risk factors used in absolute CVD-risk assessment
Among the 563 participants (aged 31–74 years), mean ages were 51.9±10.6 versus 47.7±10.8 years for males versus females, respectively. Among CVD risk factors, prevalence of smoking was the highest (75.8%), followed by systolic blood pressure ≥140 mm Hg (9.1%), fasting blood glucose ≥7 mmol/L (2.7%) and fasting blood cholesterol ≥6 mmol/L (18.1%). The trends by age and sex should be noted as the WHO/ISH charts include both of these demographic characteristics as the key defining variables in the risk charts (table 1).

Distribution of ‘absolute’ CVD risk using the WHO/ISH risk prediction charts alone
The distribution of absolute CVD risk using both sets (with and without cholesterol) is shown in table 2. When risk assessment was performed with cholesterol, 89% had a 10-year CVD risk of <20%; the corresponding proportion was 92.2% when cholesterol was not included in the calculation. The proportions with risk ≥20% (high and very high) were 11% with cholesterol versus 7.8% without. When we applied the charts without cholesterol, the percentage of the population in the high (20–29.9% 10-year risk) and very high-risk categories (≥30% 10-year risk) was less than with the chart using cholesterol (4.3 vs 5.3 and 3.6 vs 5.7, respectively), but the difference was not statistically significant. In general, males had a higher risk of CVD according to both the tools.

Concordance of the two CVD risk charts
In this study, concordance was found between the two charts for 504 (89.5%) participants (table 3). Using the with cholesterol version as the gold standard, the chart
without cholesterol overestimated CVD risk in 43 (7.6%) participants and underestimated risk in 16 (2.8%) participants. Of the 59 individuals with non-concordant CVD risk estimates, 72.8% (43/59) were overestimated (29/41 men and 14/18 women); 40.7% (24/59) belonged to low and moderate CVD risk categories that would not have drug intervention at a CVD threshold risk of ≥20% with either chart. Only 4.3% (24/563) of the total sample was misclassified vice versa need for drug intervention: risk was overestimated in 3.4% (19/563) and underestimated in 1.1% (6/563).

Comparison of drug requirement among study participants
Using the WHO guidelines for CVD risk assessment and management, (2) estimates of proportions of persons requiring medications to reduce CVD risk in this sample were similar by both with and without cholesterol charts. Using a threshold of ≥30% 10-year risk, 6.1% of those studied without measuring cholesterol were classified as requiring drugs, 4.1% of those studied were those in whom cholesterol was measured. Using a threshold of ≥20%, the proportions were 11.4% (159 of 563) of the participants would require drug treatment (10.1% antihypertensives and 18.1% lipid-lowering drugs); almost fivefold higher than without cholesterol and sevenfold higher than with the cholesterol risk approach (table 4).

DISCUSSION
Data from this study show that about 10% of the adult populations, even in a peripherally located rural population of Bangladesh, are at high risk of a CVD event in the next 10 years and half of these individuals are in the very high-risk category. These proportions are similar whether the 'with or without' cholesterol version of the WHO/ISH CVD Risk-Assessment Tool is used. The risk is in terms of a 10-year absolute CVD Risk, which is much higher than that recently reported by Cravedi et al,16 using only the without cholesterol version of the tool, in another rural Bangladeshi population. In that study, the proportion of higher risk participants is only 2.1% (very high risk 1.2% and high risk 0.9%), whereas in this study, using the same tool, the corresponding proportion is 7.9% (very high risk 3.6% and high risk 4.3%). The reasons for these discrepancies are not presently known; however, population differences related to

Table 1 Gender and age distribution and the prevalence of CVD risk factors of the study participants (n=563)

<table>
<thead>
<tr>
<th>Age group (years)</th>
<th>31–49</th>
<th>50–59</th>
<th>60–69</th>
<th>≥70</th>
<th>Total n (%)</th>
<th>Mean±SD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>152 (40.9)</td>
<td>116 (31.2)</td>
<td>74 (19.9)</td>
<td>30 (8.1)</td>
<td>372 (66.1)</td>
<td>51.9±10.6</td>
</tr>
<tr>
<td>Female</td>
<td>110 (57.6)</td>
<td>47 (24.6)</td>
<td>23 (12.0)</td>
<td>11 (5.8)</td>
<td>191 (33.9)</td>
<td>47.7±10.8</td>
</tr>
<tr>
<td>Total n (%)</td>
<td>262 (46.5)</td>
<td>163 (29.0)</td>
<td>97 (17.2)</td>
<td>41 (7.3)</td>
<td>563 (100)</td>
<td>50.5±10.9</td>
</tr>
</tbody>
</table>

Table 2 Ten-year absolute CVD risk prediction by gender, using the WHO/ISH SAER D charts, with and without cholesterol

<table>
<thead>
<tr>
<th>WHO/ISH SAER D chart</th>
<th>Gender</th>
<th>Low risk (&lt;10)</th>
<th>Moderate risk (10–19.9)</th>
<th>High risk (20–29.9)</th>
<th>Very high risk (30–39.9)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Male</td>
<td>77.7 (289/372)</td>
<td>11.3 (42/372)</td>
<td>5.9 (22/372)</td>
<td>5.1 (19/372)</td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td>80.1 (153/191)</td>
<td>8.9 (17/191)</td>
<td>4.2 (8/191)</td>
<td>6.8 (13/191)</td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td>78.5 (442/563)</td>
<td>10.5 (59/563)</td>
<td>5.3 (30/563)</td>
<td>5.7 (32/563)</td>
</tr>
<tr>
<td></td>
<td>Male</td>
<td>78.5 (292/372)</td>
<td>13.2 (49/372)</td>
<td>5.6 (21/372)</td>
<td>2.7 (10/372)</td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td>82.7 (158/191)</td>
<td>10.5 (20/191)</td>
<td>1.6 (3/191)</td>
<td>5.2 (10/191)</td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td>79.9 (450/563)</td>
<td>12.3 (69/563)</td>
<td>4.3 (24/563)</td>
<td>3.6 (20/563)</td>
</tr>
</tbody>
</table>

*χ²=0.35 p=0.557.  
†χ²=0.88 p=0.348.  
‡χ²=0.70 p=0.403.  
§χ²=2.90 p=0.088.  
genetic as well as environmental, sociodemographic and lifestyle factors may contribute to the wide difference in the prevalence of the higher risk of CVDs among the two groups. It needs to be noted that the proportion of the 10-year absolute CVD risk positive (higher than the low risk group including the moderate CVD risk group) participants (25% in the Cravedi study vs 20.2% in this study) are fairly similar in the two studies.

With the exception of the work as cited above, no other study has reported absolute CVD risk among the Bangladeshi population (using the WHO/ISH Tool or any other absolute risk scoring system). The without cholesterol version of the tool was applied in various other countries; a similar proportion of risk positive (moderate, high and very high) groups has been reported from Bolivia (11.3%) and higher proportions have been reported from Nepal (16.9%), the USA (18.2%) and Georgia (25%).

Comparative data using ‘with cholesterol’ shows considerable similarity with our findings (78.5%) for low risk (<10%) group in Pakistan, Georgia, Nepal, Nigeria, Mongolia and Cuba (79.2%, 83.1%, 87.2%, 86%, 89.6% and 89.7% respectively); and somewhat 10% higher in Iran, Sri Lanka, Malaysia, China and Cambodia (93.9%, 94.9%, 94.4%, 96.1% and 97%, respectively). However, among the moderate or high-risk groups, males show a higher preponderance in almost all countries except Sri Lanka and Nepal, which is similar to our findings.

The major focus of this study was to find out the level of agreement between the results generated by the without and with cholesterol versions of the WHO/ISH Tool. From the frequency distribution (table 2), it can be seen that the results from the two versions do not differ significantly when both genders are considered as a

<table>
<thead>
<tr>
<th>CVD risk With cholesterol</th>
<th>Low risk (&lt;10)</th>
<th>Moderate risk (10–19.9)</th>
<th>High risk (20–29.9)</th>
<th>Very high risk (30–39.9)</th>
<th>Total (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low risk</td>
<td>432 (76.7)</td>
<td>12 (2.1)</td>
<td>5 (0.9)</td>
<td>1 (0.2)</td>
<td>450 (79.9)</td>
</tr>
<tr>
<td>Moderate risk</td>
<td>10 (1.8)</td>
<td>41 (7.3)</td>
<td>11 (2.0)</td>
<td>7 (1.2)</td>
<td>69 (12.3)</td>
</tr>
<tr>
<td>High risk</td>
<td>0</td>
<td>3 (0.5)</td>
<td>14 (2.5)</td>
<td>7 (1.2)</td>
<td>24 (4.3)</td>
</tr>
<tr>
<td>Very high risk</td>
<td>0</td>
<td>3 (0.5)</td>
<td>0</td>
<td>17 (3.0)</td>
<td>20 (3.6)</td>
</tr>
<tr>
<td>Total (%)</td>
<td>442 (78.5)</td>
<td>59 (10.5)</td>
<td>30 (5.3)</td>
<td>32 (5.7)</td>
<td>563 (100.0)</td>
</tr>
</tbody>
</table>

Concordance: 89.5% (504/563). Non-concordance: 10.5% (59/563).

Overestimate: 7.6% (43/563), Underestimate: 2.8% (16/563).

Misclassification for CVD risk threshold ≥20%: 4.3% (24/563).

Overestimate: 3.4% (19/563), Underestimate: 1.1% (6/563).

κ Value (0.705, p<0.001).


Table 4 Association of drug requirements for CVD prevention among the study population as per total CVD risk assessment, with and without cholesterol, and single risk factor line

<table>
<thead>
<tr>
<th>Approaches</th>
<th>Variants</th>
<th>Participants (n=563)</th>
<th>Persons requiring drugs</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Threshold ≥30% No.</td>
<td>Threshold ≥20% No.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>%</td>
<td>%</td>
</tr>
<tr>
<td>Total CVD risk without cholesterol</td>
<td>Elevated risk per charts alone</td>
<td>32</td>
<td>5.7</td>
</tr>
<tr>
<td></td>
<td>Charts normal with BP ≥160/100</td>
<td>2</td>
<td>0.36</td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td>34*</td>
<td>6.06†</td>
</tr>
<tr>
<td>Total CVD risk with cholesterol</td>
<td>Elevated risk per charts alone</td>
<td>20</td>
<td>3.55</td>
</tr>
<tr>
<td></td>
<td>Charts normal with BP ≥160/100</td>
<td>2</td>
<td>0.36</td>
</tr>
<tr>
<td></td>
<td>Charts normal with TC ≥8</td>
<td>1</td>
<td>0.18</td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td>23§</td>
<td>4.09¶</td>
</tr>
<tr>
<td>Single risk factor</td>
<td>BP ≥140/90</td>
<td>57*</td>
<td>10.1</td>
</tr>
<tr>
<td></td>
<td>TC ≥6</td>
<td>102</td>
<td>18.1</td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td>159§</td>
<td>28.2</td>
</tr>
</tbody>
</table>

*Without cholesterol versus single risk factor, threshold ≥30%; χ²=6.32, p<0.012.
†Without cholesterol, threshold ≥30% versus without cholesterol, threshold ≥20%; χ²=10.06, p<0.002.
‡With cholesterol versus single risk factor, threshold ≥20%; χ²=0.45, p<0.500.
§With cholesterol versus single risk factor, threshold ≥30%; χ²=123.9, p<0.001.
¶With cholesterol, threshold ≥30% versus with cholesterol, threshold ≥20%; χ²=8.77, p<0.003.
**With cholesterol versus single risk factor, threshold ≥20%; χ²=74.5, p<0.001.

BP, blood pressure; CVD, cardiovascular disease; TC, total cholesterol.

combined group. However, when males and females are analysed separately, wide discrepancies are found in the results of the two charts. There is a gross chance of over-estimation (by about 71%) of very high risk among males and (by about 78%) of high risk among females in using without cholesterol compared with the cholesterol version. Similarly, when the concordance between the two versions was statistically tested, the agreement between the two versions was fair (89.5%) considering the subject group as a whole. However, repeating the tests separately in males and females resulted in similar levels of concordance (89% and 90.6%, respectively). On the basis of the overall population, the concordance rate in this study is similar to that in a Cuban study, but it is higher than that in a study which applied a Framingham CVD risk score using cholesterol and/or BMI formulae.

In this study, the agreement was further explored by an empirical technique using the need for medication as suggested by the two versions of the WHO/ISH Tool. It can be seen that, compared to the single factor risk assessment approach, a much less proportion of participants require drug treatment when they are scored by the WHO/ISH Tool. However, this percentage of the population is about fivefold to sevenfold higher (whether the threshold of the absolute risk is >30% or >20%) when suggestion is generated by the with cholesterol version compared to the without cholesterol version of the Tool. It thus appears that the reduction of the CVD risk threshold from ≥30% to ≥20% greatly improves the diagnosis of patients and did not introduce overprescription of drugs. However, both tools assessed better targeting of those more likely to develop CVD and, compare with the single-risk-factor approach, still showed either an underestimate or less need for drugs in a substantial proportion of participants. There is still no universal consensus on the threshold level (>30% vs 20%) that is required to make a decision for drug treatment and the question may still be raised whether the absolute risk factor approaches may introduce undertreatment. The WHO proposes that the CVD risk threshold for intensive intervention across a 10-year span should be based on the resource levels of respective countries. Moreover, with or without cholesterol guidelines are not compared to any gold standard, that is, the WHO risk score (for region) is based on the modelling of various data from different countries but not on real data in Bangladesh (i.e., there are no cohort studies in Bangladesh or neighbouring countries providing actual prospective CVD outcome data in relation to risk factors in these countries). Therefore, it is obvious that much of the data, particularly those based on longitudinal studies, need to be generated in Bangladesh to initiate more evidence-based discussion in this field.

In conclusion, about one-fifth of the adult people in Bangladesh, even in a remote rural area, seem to be at risk of developing CVDs within 10 years. Among this, one-fifth, about 25%, are at high risk and another 25% are at very high risk of developing the disorders with males and females being almost equally vulnerable. Our data indicate that use of the with cholesterol version of the WHO/ISH 10-year absolute CVDs risk assessment could avoid overestimation of the risk, particularly in the high-risk and very high-risk subgroups, and undertreatment of participants who should be treated with medication. On the other hand, a very high concordance between the with and without cholesterol tools indicates that with the resource limitations and less facilities for laboratory investigations settings, the without cholesterol tools allow for better targeting of those who are more likely to develop cardiovascular diseases. The finding also indicates that a large-scale study could be conducted to verify the pattern.

**References**


Application of two versions of the WHO/international society of hypertension absolute cardiovascular risk assessment tools in a rural Bangladeshi population

Kaniz Fatema, Nicholas Arnold Zwar, Abul Hasnat Milton, Bayzidur Rahman and Liaquat Ali

BMJ Open 2015 5:
doi: 10.1136/bmjopen-2015-008140

Updated information and services can be found at:
http://bmjopen.bmj.com/content/5/10/e008140

These include:

References
This article cites 17 articles, 7 of which you can access for free at:
http://bmjopen.bmj.com/content/5/10/e008140#BIBL

Open Access
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

- Evidence based practice (437)
- Health services research (848)
- Public health (1370)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/